Sabby Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Sabby Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-28,626	Closed	-$443K	–	242
2017 Q1	$410K	Sell	28,626 -41,414	-59%	-$614K	0.02%	191
2016 Q4	$969K	Buy	+70,040	New	+$1.12M	0.06%	148
2016 Q1	–	Sell	-67,710	Closed	-$710K	–	327
2015 Q4	$901K	Sell	67,710 -193,885	-74%	-$2.38M	0.05%	198
2015 Q3	$2.81M	Sell	261,595 -57,180	-18%	-$624K	0.12%	129
2015 Q2	$2.57M	Sell	318,775 -448,625	-58%	-$3.29M	0.09%	144
2015 Q1	$5.07M	Buy	767,400 +738,443	+2,550%	+$5.04M	0.21%	76
2014 Q4	$184K	Buy	+28,957	New	+$233K	0.01%	214
2014 Q1	–	Sell	-142,857	Closed	-$1.8M	–	262
2013 Q4	$1.8M	Buy	+142,857	New	+$2.27M	0.11%	90

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UIM

USS Investment Management London, United Kingdom $27.8B AUM 39.42% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sabby Management's LXRX Position: Q2 2017 in Review

Sabby Management sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2017, closing a stake of 28,626 shares — an estimated $443K sold.

Sabby Management first reported a position in LXRX in Q4 2013 and held it in 8 quarters. The position peaked at $5.07M in Q1 2015. 136 funds tracked by Wall St. Rank hold LXRX as of Q2 2017.

Sabby Management reported no remaining Lexicon Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Sabby Management sold 28,626 Lexicon Pharmaceuticals shares in Q2 2017, an estimated $443K.
Sabby Management first reported a position in Lexicon Pharmaceuticals in Q4 2013 and held it in 8 quarters.
Sabby Management's Lexicon Pharmaceuticals position peaked at $5.07M in Q1 2015.
136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2017.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.